Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2019

Immune Checkpoints Activators - Competitive Landscape, Technology and Pipeline Analysis, 2019

  • Pages: 282
  • Geography: Global
  • Delivery Timeline: 24 Hours
  • Publication: Jul, 2019
  • SKU: DISR0002
  • Single User License
    (20% Off)
    $2,360.00
  • Site License
    (30% Off)
    $4,130.00
  • Global License
    (40% Off)
    $5,310.00
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight's, "Immune Checkpoints Activators- Competitive Landscape, Technology and Pipeline Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Immune Checkpoints Activators. This report provides information on the therapeutic development based on Immune Checkpoints Activators mechanism of action dealing with around 40+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Immune Checkpoints Activators therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 20+ active companies involved in the therapeutic development of the products.
Scope

• The report provides competitive pipeline landscape of Immune Checkpoints Activators
• The report provides the marketed drugs information including its sales, development activities and details of patent expiry
• The report provides the insight of current and future market for Immune Checkpoints Activators
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Immune Checkpoints Activators pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Immune Checkpoints Activators and also provide company profiling
• The report also gives the information of dormant pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type ?
Reasons to Buy
• Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
• Complete MOA intelligence and complete understanding over therapeutics development for Immune Checkpoints Activators
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
• Devise corrective measures for pipeline projects by understanding Immune Checkpoints Activators pipeline depth and focus of Indication therapeutics
• Developing strategic initiatives to support your drug development activities.
• Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.
• Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Executive Summary
Executive Summary Snapshot
Immune checkpoints Activator Overview
Rationale for targeting Immune checkpoint Agonist in oncology
Stimulatory checkpoint molecules
Advantages of Immune checkpoint Activators
Constraints of Immune Checkpoint Activators
Future of Immune Checkpoint Activators in Cancer Therapy
ImmuneCheck Activators Analysis
ImmuneCheck Activators- Market Analysis
Companies received Grants for Immune checkpoints Activator
Companies Investment Details for Future Development
Licensing Opportunities
Market Drivers
Market Barriers
ImmuneCheck Activators - Pipeline Analysis
Number of Products
Therapeutic Areas Targeted
Stages of Development
Companies Involved
Technological Platform Utilized
Clinical Trials Analysis
Clinical Products and Study Completion Year
Studies Analysisfor the Key Targets Antigens
Pipeline Therapeutics
Therapeutics under Development by Companies
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-Clinical and Discovery Products
Comparative Analysis
Therapeutic Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Stage and Route Of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Discontinued Products
Comparative Analysis
Appendix
DelveInsight Consulting Services
About DelveInsight
Contact Us
Disclaimer

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Table 1: B7 & CD28 Family Members
Table 2: Collaboration and Deal Values for Immune checkpoints Activators, 2017
Table 3: Companies of Immune checkpoints Activators received grants, 2017
Table 4: Companies Investment Details for Immune checkpoints Activators, 2017
Table 5: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 6: ImmuneCheck Targets-Number of Drugs (N) and Indications
Table 7: ImmuneCheck Activators Targets Antigens and Companies
Table 8: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Table 9: Number of Products Under Development for Immune checkpoints Activator, 2017
Table 10: Number of Products under Development by Companies, 2017
Table 11: Mid Stage Products (Phase II), 2017
Table 12: Early Stage Products (Phase I ), 2017
Table 13:Pre-Clinical and Discovery Products, 2017
Table 14: Assessment by Monotherapy Products, 2017
Table 15: Assessment by Combination Products, 2017
Table 16: Assessment by Route Of Administration, 2017
Table 17: Assessment by Stage and Route Of Administration, 2017
Table 18: Assessment by Molecule Type, 2017
Table 19:Assessment by Stage and Molecule Type, 2017
Table 20: Discontinued Products, 2017
 

Figure 1: Types of Immune Checkpoint receptors
Figure 2: Immune Check Targets-Companies and Collaborations (N) and Investment (Million)
Figure 3: ImmuneCheck Targets-Number of Products (N) and Total Share(%)
Figure 4: ImmuneCheck Targets-Number of Drugs (N) and Indications
Figure 5: ImmuneCheck Targets-Number of Products (N) and Stages of Development
Figure 6: ImmuneCheck Targets-Number of Products (N) and Stages Of Development
Figure 7: ImmuneCheck Targets-Number of Products (N) and Technology Used
Figure 8: ImmuneCheck Targets-Number of Products (N) and Technology used
Figure 9: ImmuneCheck Targets-Number of Trials (N) and Study Completion Year
Figure 10: Number of Products under Development for Immune checkpoints Activator, 2017
Figure 11: Mid Stage Products (Phase II), 2017
Figure 12:Early Stage Products (Phase I and IND), 2017
Figure 13:Pre-Clinical and Discovery Products, 2017
Figure 14: Assessment by Monotherapy Products, 2017
Figure 15: Assessment by Combination Products, 2017
Figure 16: Assessment by Route of Administration, 2017
Figure 17: Assessment by Stage and Route of Administration, 2017
Figure 18: Assessment by Molecule Type, 2017
Figure 19: Assessment by Stage and Molecule Type, 2017
Figure 20:Discontinued Products, 2017

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.